Loading
Absci
AbSci Corporation operates as a synthetic biology company. The Company translates and unifies biologic drug discovery and development processes with its integrated drug creation platform. AbSci serves customers in the United States.
Funding
Every round, secondary, debt facility or acquisition involving Absci that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—